Viracta Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mark Rothera

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	40.5%
Permanencia del CEO	2yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mark Rothera en comparación con los beneficios de Viracta Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

Compensación vs. Mercado: La compensación total de Mark($USD1.46M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD408.13K).

Compensación vs. Ingresos: La compensación de Mark ha sido consistente con los resultados de la empresa en el último año.

CEO

Mark Rothera (61 yo)

2yrs

Permanencia

US$1,456,596

Compensación

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	sin datos
Darrel Cohen	Chief Medical Officer	1.1yrs	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.8yrs	sin datos	sin datos
Ronald Berenson	Co-Founder and Consultant	13.8yrs	sin datos	sin datos
George Hillman	Co-Founder	no data	sin datos	sin datos
Thalia Papayannopoulou	Co-Founder	no data	sin datos	sin datos
Robert Williams	Co-Founder	no data	sin datos	sin datos
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Michael Faerm	Chief Financial Officer	less than a year	sin datos	sin datos
Ayman El-Guindy	Chief Scientific Officer	3.2yrs	sin datos	sin datos
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.5yrs	sin datos	sin datos
Patric Nelson	Senior Vice President of Business Development & Corporate Strategy	3.2yrs	sin datos	sin datos

3.2yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RYI se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	sin datos
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Ivor Royston	Director	3.6yrs	US$90.76k	2.11% $ 168.5k
Thomas Darcy	Independent Director	3.6yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	6yrs	sin datos	sin datos
Carl June	Member of Scientific Advisory Board	6yrs	sin datos	sin datos
Barry Simon	Independent Director	3.5yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.6yrs	US$210.27k	0.30% $ 23.7k
Lawrence Young	Member of Scientific Advisory Board	6yrs	sin datos	sin datos
Robert Baiocchi	Member of Scientific Advisory Board	6yrs	sin datos	sin datos
Pierluigi Porcu	Member of Scientific Advisory Board	6yrs	sin datos	sin datos
Stephen Rubino	Independent Director	3.5yrs	US$108.26k	0% $ 0

3.6yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de RYI se considera experimentada (3.3 años de antigüedad promedio).

Viracta Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

New major risk - Market cap size

New minor risk - Shareholder dilution

New major risk - Financial position

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

New major risk - Revenue and earnings growth

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics, Inc. Announces Executive Changes

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad